# TScan Therapeutics, Inc.

**TCRX**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001783328


# None

### No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $228.8M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data; fortress balance sheet<br>not computable: dilution, distress |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 4, 2026<br>247 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026 |
| **Last close** | $0.18<br>2026-11-05; market equity $4.3M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 4, 2026*

- Competition" in this Annual Report on Form 10-K. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors' products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 83.9** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | 1.9% | (6.6%) | | 83.9 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 52.9** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *liabilities and a nearby cover-page share count are required at 2026-06-30* | | | | | | |
| Altman Z double-prime | (5.99) | (0.37) | | 54.7 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | (49.05x) | (4.51x) | | 83.1 | 78 | 2025-12-31 |
| Current ratio | 8.41x | 2.94x | | 21.0 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 63.1** | | | | | | |
| Revenue growth, three-year compound | (8.6%) | 10.0% | | 84.4 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | 4.7% | 2.2% | | 41.9 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *two annual share counts are required; found 1* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 119,872,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-11-05 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (83.8%) | (2.1%) | 4 |
| Distance from 52-week high | (87.3%) | (30.4%) | 5 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (3,205.5%) | (1.0%) | 0 |
| Book value to price | 15.83 | 0.29 | 99 |
| Sales to price | 2.37 | 0.30 | 92 |
| Composite equity issuance, five years | not computable | 21.4% | |
| Relative strength against the sector, log excess return | (1.99) | (0.19) | 4 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | pass |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $100.2M |
| Operating cash flow, four quarters | -$116.3M |
| Months of runway | 10.3 |
| Days since last periodic filing | 86 (10-Q received Aug 12, 2026) |
| Median daily dollar volume, 63 sessions | $198,281 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$129.8M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$135.3M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 3 | assets | us-gaap:Assets | $228.8M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 4 | assets | us-gaap:Assets | $371.1M | 2024-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 5 | current assets | us-gaap:AssetsCurrent | $157.2M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $18.7M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$504.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$135.8M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 9 | book equity | us-gaap:StockholdersEquity | $123.1M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 10 | liabilities | us-gaap:Liabilities | $105.7M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 11 | total debt | us-gaap:LongTermDebt | $32.5M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $152.4M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 13 | depreciation amortization | us-gaap:Depreciation | $2.9M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 14 | interest expense | us-gaap:InterestExpense | $2.8M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $10.3M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.8M | 2024-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $21.0M | 2023-12-31 | 2025-03-05 | 10-K | 25-033077 |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $13.5M | 2022-12-31 | 2024-03-06 | 10-K | 24-026875 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.4M | 2025-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$110.8M | 2024-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.8M | 2024-12-31 | 2026-03-04 | 10-K | 26-089884 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$61.4M | 2023-12-31 | 2025-03-05 | 10-K | 25-033077 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.1M | 2023-12-31 | 2025-03-05 | 10-K | 25-033077 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$66.5M | 2022-12-31 | 2024-03-06 | 10-K | 24-026875 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.2M | 2022-12-31 | 2024-03-06 | 10-K | 24-026875 |
| 26 | assets | us-gaap:Assets | $272.1M | 2023-12-31 | 2025-03-05 | 10-K | 25-033077 |
| 27 | assets | us-gaap:Assets | $199.1M | 2022-12-31 | 2024-03-06 | 10-K | 24-026875 |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 23,976,942 | 2022-03-04 | 2022-03-09 | 10-K | 22-003175 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.